Overview

Study of BHV-1300 in Graves' Disease

Status:
RECRUITING

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Phase:

PHASE1

Details

Lead Sponsor:

Biohaven Therapeutics Ltd.